<SEC-DOCUMENT>0001654954-19-011884.txt : 20191021
<SEC-HEADER>0001654954-19-011884.hdr.sgml : 20191021
<ACCEPTANCE-DATETIME>20191021071856
ACCESSION NUMBER:		0001654954-19-011884
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191015
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191021
DATE AS OF CHANGE:		20191021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanara MedTech Inc.
		CENTRAL INDEX KEY:			0000714256
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				592220004
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11808
		FILM NUMBER:		191158745

	BUSINESS ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-529-2300

	MAIL ADDRESS:	
		STREET 1:		1200 SUMMIT AVE
		STREET 2:		SUITE 414
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WOUND MANAGEMENT TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20080611

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MB SOFTWARE CORP
		DATE OF NAME CHANGE:	19960805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INAV TRAVEL CORPORATION
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sanara_8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">UNITED
STATES</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">FORM
8-K</font><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Arial; font-size: 7px"><font style="font-size: 13px">
<font style="font-family: Times New Roman;">C</font></font><font style="font-family: Times New Roman;">URRENT <font style="font-size: 13px">R</font>EPORT</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Date of Report (Date of earliest event reported): October 15,
2019</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
SANARA MEDTECH INC.</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;(Exact name of registrant as specified in its
charter)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">
59-2219994</font><br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 34%">
<div style="text-align: center"><font>&#xA0; <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Texas</font></font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction of
incorporation)</font>&#xA0;<br></font></div>
</td>
<td style="width: 33%">
<div style="text-align: center"><font>&#xA0; <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">000-11808&#xA0;</font></font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(Commission
File Number)(I.R.S. Employer Identification
No.)</font>&#xA0;<br></font></div>
</td>
<td style="width: 33%">
<div style="text-align: center"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">59-2219994</font></font></font></div>
<div style="text-align: center"><font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(I.R.S.
Employer Identification No.)</font></font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 34%">
<div style="text-align: center"><font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">1200
Summit Avenue, Suite 414</font></font> <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Fort
Worth, Texas&#xA0;</font></font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(Address
of principal executive offices)&#xA0;&#xA0;</font></font></div>
</td>
<td style="width: 33%">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 33%; vertical-align: bottom;">
<div style="text-align: center"><font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">76102</font></font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(zip
code)</font>&#xA0;<br></font></div>
</td>
</tr></table>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Registrant&#x2019;s telephone number, including area code:
(817)-529-2300</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="font-family: Times New Roman; font-size: 13px;">Securities
registered pursuant to Section 12(b) of the Act: None</font></div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font><font style="font-family: Times New Roman; font-size: 13px;">Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></font></div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 44px"><font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman;">&#x2610;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
<div style="text-align: left; display: table-cell"><font><font style="font-family: Times New Roman; font-size: 13px;">Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)</font></font></div>
</div>
</div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 44px"><font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman;">&#x2610;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
<div style="text-align: left; display: table-cell"><font><font style="font-family: Times New Roman; font-size: 13px;">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></font></div>
</div>
</div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 44px"><font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman;">&#x2610;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
<div style="text-align: left; display: table-cell"><font><font style="font-family: Times New Roman; font-size: 13px;">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</font></font></div>
</div>
</div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 44px"><font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman;">&#x2610;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
<div style="text-align: left; display: table-cell"><font><font style="font-family: Times New Roman; font-size: 13px;">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</font></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 1px; text-indent: 0px">
<font><font style="font-family: Times New Roman; font-size: 13px;">Indicate by check
mark whether the registrant is an emerging growth company as
defined in in Rule 405 of the Securities Act of 1933 (&#xA7;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;240.12b-2 of this chapter).</font></font></div>
<div><font>&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font><font style="font-family: Times New Roman; font-size: 13px;">Emerging growth
company <font style="font-family: Times New Roman;">&#x2610;</font></font></font></div>
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#x2610;</font></div>
<div><font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; break-after: page; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
3.02 Unregistered Sales of Equity Securities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 15, 2019, Sanara MedTech Inc. (the &#x201C;Company&#x201D;)
closed a private placement offering of 1,204,820 shares of its
common stock at a price of $8.30 per share. All shares are being
sold by the Company as newly issued shares. The purchasers in the
offering consist of related party entities to three members of the
Company&#x2019;s Board of Directors. The transaction was approved by
all of the disinterested Directors of the Company. The price per
share was determined by a special committee of the Board comprised
of disinterested Directors who considered an independent
third-party valuation of the offering price and other relevant
information.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The $10
million of cash proceeds of the offering are expected to be used to
fund milestone payments under current and future product license
agreements, repayment of indebtedness under the Company&#x2019;s
bank line of credit, and operating expenditures, including clinical
studies and continued expansion of the Company&#x2019;s sales
force.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
shares of common stock sold in the transaction were not registered
under the Securities Act of 1933. The Company relied on the
exemption from registration in Section 4(a)(2) of the Securities
Act of 1933, a transaction not involving a public offering. The
Company sold the shares of common stock, without general
solicitation or advertising, to three accredited investors who
represented themselves as being fully informed, with the knowledge
and experience to be capable of evaluating the merits and risks of
the transaction, and with no present intention of selling or
distributing the shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 16, 2019, the Company issued a press release announcing
this private placement transaction. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form
8-K.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
9.01 Financial Statements and Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(d)
Exhibits:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 17px">
<div style="display: table-row">
<div style="display: table-cell; width: 127px"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Exhibit
No.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Description</font></div>
</div>
</div>
<div style="display: table; margin-left: 17px">
<div style="display: table-row">
<div style="display: table-cell; width: 127px"><font style="font-family: Times New Roman; font-size: 13px"><a href="sanara_ex991.htm"><font style="font-family: Times New Roman; font-size: 13px">99.1</font></a>
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
</font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">Press Release
issued October 16, 2019, filed herewith.</font>&#xA0;</font>
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 36px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SIGNATURE</font></div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Sanara
MedTech Inc.</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0; <font style="font-family: Times New Roman; font-size: 13px;">Date: October 21,
2019&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/&#xA0;
<font style="font-family: Times New Roman; font-size: 13px;">Michael D.
McNeil</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">Michael D.
McNeil</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">Chief
Financial Officer</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sanara_ex991.htm
<DESCRIPTION>PRESS RELEASE ISSUED OCTOBER 16, 2019, FILED HEREWITH
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold"><font style="font-family: Times New Roman; font-size: 13px">EXHIBIT
99.1</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center"><img src="sanara_logo.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 312px; margin-right: 0px; text-indent: -288px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Sanara
MedTech Inc. Announces Closing of $10,000,000 Private Placement of
Common Stock</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 5px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">FORT WORTH, TX / ACCESSWIRE / October 16, 2019
/ Sanara MedTech Inc</font>. (OTCQB: SMTI). Based in Fort Worth,
Texas, Sanara MedTech Inc. ("Sanara"), a provider of surgical and
chronic wound care products dedicated to improving patient
outcomes, announced today that it has closed a private placement
offering of 1,204,820 shares of its common stock at a price
of</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 4px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">$8.30
per share. All shares are being sold by Sanara as newly issued
shares. The purchasers in the offering consist of related party
entities to three members of Sanara's Board of Directors. The
transaction was approved by all of the disinterested Directors of
Sanara. The price per share was determined by a special committee
of the Board comprised of disinterested Directors who considered an
independent third-party valuation of the offering price and other
relevant information.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The $10
million of cash proceeds of the offering are expected to be used to
fund milestone payments under current and future product license
agreements, repayment of indebtedness under Sanara's bank line of
credit, and operating expenditures, including clinical studies and
continued expansion of Sanara's sales force.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
shares of common stock sold in the transaction have not been
registered under the Securities Act of 1933 and may not be offered
or sold in the United States absent registration or an applicable
exemption from registration requirements.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sanara
MedTech Inc. markets and distributes wound and skincare products to
physicians, hospitals, clinics, and all post-acute care settings.
Its products are primarily sold in the North American advanced
wound care and surgical tissue repair markets.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Information
about Forward-Looking Statements</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
statements in the press release that relate to the Company's
expectations with regard to the future impact on the Company's
results from new products in development and any other statements
not constituting historical facts are "forward-looking statements,"
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results. This
document may contain forward-looking statements concerning the
Company's operations, current and future performance and financial
condition. These items involve risks, contingencies and
uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition,
pricing, the ability to consummate and integrate acquisitions, and
other risks, contingencies and uncertainties detailed in the
Company's SEC filings, which could cause the Company's actual
operating results, performance or business plans or prospects
<font style="font-family: Times New Roman; font-size: 13px">to
differ materially from those expressed in, or implied by these
statements. The Company undertakes no obligation to revise any of
these statements to reflect the future circumstances or the
occurrence of unanticipated events.</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Investor
Contact:</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Callon
Nichols, Director of Investor Relations 713-826-0524</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-family: Times New Roman; font-size: 13px">
CNichols@sanaramedtech.co</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">SOURCE:</font> Sanara MedTech
Inc.</font>&#xA0;<br>
<br></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<br>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sanara_logo.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sanara_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MX]4F!W3"%=V0<9!QGG%=D!6;JN+M#30V]C&?Q:ZG/:MX(T#7;^.^U&P2:XC
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M9(_&5K<X^26U4 ^X)S_.O;O#.H1:GX9TV\A8,DMNAR/4#!'YUR_Q3\(/XFT
M2VB[KZSS)$H_Y:#NO^%>8^ /B/+X0WZ5JD4LE@7/W?OP-GGCTSVJ;>TIJVZ!
M/V=1WZGT;2,>*Y6+XD>$IH!*NNVJC&<.2I'X'FN*\7_%ZWG@?3/"ZRW-U/\
MNQ<!" ,\?(.I-9*G)O8V=6*ZG ^.M0CU+XH7,L3!D2YCB!'<J0#^N:^FT^XO
MTKY+O='N]#\1VMI??\?1:*20'J"Q!P?4U]:+]Q?I6V(22BC'#N\I,^:-*_Y+
M6G_89?\ ]&-7TR.M?,VE?\EK3_L,O_Z,-?30ZTJ^Z]"L/LQ:\(^/?_(:T?\
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M);Z7;*T\C..H4?>;'Z"H?@?SXYG_ .O)_P#T):Z(0Y:3ON82ES5%8]H\<?\
M(DZQ_P!>K_RKRGX"C_B;ZQ_UPC_F:]6\<?\ (DZQ_P!>K_RKRGX"?\A?6?\
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M_C276ICIU[<&>.T2'<\DF=Q&<YP#R>*G\1G1_&GA'1=>U_45TB]96C7$>\2
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M:-8OBC&$ 7?;9;'?@_X5VZU%6*3374Z,+4G)-2UL[#Z***R.H**** "BBB@
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M9%R%)[KGOCVIMGK%[/=V,<EO&D=U$SGD[A@=?IDBI[K3+NZTR6WEF0R3,N_
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MK&,L%&,!B>QKHQTKG=#9X+V2RD@MMT<8/GV_0^Q!Z&NB'2I&A:***!A1110
M4444 %%%% !1110 4F*** $;I5+3[*TMA++:6XA,[EY,+@LWJ:**.@NI::%&
M96902AROM4@%%% Q<4F*** %HHHH **** "BBB@ I,"BB@ P*,444 &!1@44
M4 &!1@444 &!1@444 %%%% !BC HHH ,#THP*** #%&!110 8HP*** # ]*,
M"BB@ Q37C21=KJ&4]01D444 )'#'$NV-%4>BC J2BB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
